Previous 10 | Next 10 |
Late March, CytoDyn ([[CYDY]] +24.5%) announced that the Philippines FDA approved the use of Vyrologix (leronlimab) to treat a COVID-19 patient under compassionate special permit.38 hours after the subcutaneous injection of leronlimab, the patient has ‘significantly’ i...
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, annou...
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...
CytoDyn (CYDY) will host an investment community webcast on Tuesday, April 6, 2021 at 4:00 pm ET. Management will provide a full update on Company activities, including recent COVID-19 initiatives and information on active trials in COVID-19, NASH and cancer. Management will provide appr...
VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...
After several weeks of discussions with the FDA and analysis of CD12 trial data, CytoDyn (CYDY) has filed a new protocol for leronlimab to extend treatment to four weeks.The Company believes four weeks of leronlimab treatment to be sufficient to calm the cytokine storm and to have a posi...
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Com...
RADNOR, Pa., March 31, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds CytoDyn Inc. (OTCMKTS: CYDY) (“CytoDyn”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Western Dis...
Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value of 0.021 VANCOUVER, Washington, March 30, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnolog...
CytoDyn (CYDY) announces that the Republic of the Philippines, Department of Health, Food and Drug Administration has approved the use of leronlimab to treat a COVID-19 patient under Compassionate Special Permit ((CSP)) pursuant to FDA Order No. 2016-005. The Company is shipping leronlimab to...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...